Order Article Reprints

Maranto C, Udhane V, Jia J, Verma R, Müller-Newen G, LaViolette PS, Pereckas M, Sabharwal L, Terhune S, Pattabiraman N, et al. Correction: Maranto et al. Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers 2020, 12, 3412. Cancers. 2025; 17(6):932. https://doi.org/10.3390/cancers17060932

Maranto, Cristina, Vindhya Udhane, Jing Jia, Ranjit Verma, Gerhard Müller-Newen, Peter S. LaViolette, Michael Pereckas, Lavannya Sabharwal, Scott Terhune, Nagarajan Pattabiraman, and et al. 2025. "Correction: Maranto et al. Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers 2020, 12, 3412" Cancers 17, no. 6: 932. https://doi.org/10.3390/cancers17060932

Maranto, C., Udhane, V., Jia, J., Verma, R., Müller-Newen, G., LaViolette, P. S., Pereckas, M., Sabharwal, L., Terhune, S., Pattabiraman, N., Njar, V. C. O., Imig, J. D., Wang, L., & Nevalainen, M. T. (2025). Correction: Maranto et al. Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers 2020, 12, 3412. Cancers, 17(6), 932. https://doi.org/10.3390/cancers17060932